Multiple Sclerosis is a disease that has both physical and emotional symptoms. Emotional symptoms such as stress, anxiety, worry, fear, frustration, and depression are common, and can be both a reaction to the disease and a symptom of the disease. Additional reasons why an individual with MS may have neuropsychiatric symptoms include the MS disease course, a reaction to a disease-modifying therapy, or a biologically mediated reaction / pathophysiology. This article addresses five ways to deal with emotional stress. To read this article in its entirely start on page 26 at http://msfocusmagazine.org
Living with MS can definitely take a toll on your mood and emotional health. Often, people living with MS experience the loss of the person they were prior to the diagnosis, their social / familiar / professional roles, and physical ability. Frustration can become a recurring feeling when faced with the daily reminder of physical and cognitive challenges or the changes that have occurred over time. Questions about the future cause worry about what will happen next. To read the rest of this article with some great ideas, to address this issue read more starting on page 12 at http://msfocusmagazine.org
Evobrutinib (M2951) is a oral medication being evaluated for potential use in relapsing forms of multiple sclerosis and in secondary-progressive MS. The agent inhibits Bruton’s tyrosine kinase (BTK), an enzyme that regulates the function of B cells and macrophages, components of the immune system shown to play a role in MS.
A recent Phase 2 study examined how various doses of evobrutinib affected the total number of T1 gadolonium-enhancing lesions seen on magnetic resonance imaging (MRI) at weeks 12, 16, 20, and 24 of trearment. The study also assessed safety, the annualized relapse rate (ARR), and MRI findings at week 24 and 48 to read more on this click here https://mymsaa.org/news/new-in-ms-research-july-2019/#7
EHP-101, a cannabidiol-based experimental therapy for multiple sclerosis, was able to recover myelin in damaged nerve fibers and lessen neuroinflammation in a mouse model of MS, data show.
Emerald Health Therapeutics, the manufacturer of EHP-101 also announced plans to open Phase 2 clinical trials in patients by the close of this year.
The data on EHP-101 were shared at the 29th Annual Symposium of the International Cannabinoid Research Society (ICRS), Held June 30 – July 3 in Maryland, and suggest that EHP_101 may be a potential remyelination therapy. Click on the link to find the rest of this article at http://multiplesclerosisnewstoday.com released on July 9th, 2019, By Ana Pena
Back in 1994, shortly after she began work on her doctorate at the University of Athens and Greece’s Pasteur Institute, Katerina Akassoglou, PhD, made an important discovery. She and her fellow researchers found that mice that had certain types of immune system-regulating molecules in their brains developed mobility symptoms similar to those experienced bu people with multiple sclerosis.
Scientists at that time didn’t know about how immune cells acted inside the brain, especially in people with MS. Most of the studies prior to Akassoglou’s work focused on the role of the immune system in the body. The brain’s immune system was a whole new frontier, with the potential for more treatment options and targets for MS therapies than previously thought.
read this article in its entirely at http://nationalMSsociety.org/momentum
New research focusing on women with multiple sclerosis who are pregnant is shedding light on how the disease can affect them both during and after pregnancy. Key findings of two studies conducted by Maria Houtchens, MD, and her research team at Harvard Medical School and Brigham and Women’s Hospital show that women with MS are getting pregnant, although most do not use disease-modifying therapies for a year before and a year after pregnancy. Women with MS also tend to have more complications around the time of pregnancy compared to women without MS. Two-thirds of people with MS are women, and most are young when they get the MS diagnosis. To read this full article http://nationalMSsociety.org/momentum
The US Food and Drug Administration (FDA) has approved siponimod (Mayzent, Novartis) to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive (SP) disease, the agency announced.
Approval was based on results of the phase 3 trial, which randomly assigned 1651 patients with SPMS and an Expanded Disability Status Scale score of 3.0 to 6.5 to oral siponimod 2 mg once daily (1105 patients) or placebo (546 patients) for up to 3 years or until the occurrence of a prespecified number of confirmed disability progression events.
For most people, MS starts with a relapsing-remitting course, in which episodes of worsening function (relapses) are followed by recovery periods (remissions). These remissions may not be complete and may leave patients with some degree of residual disability. Many, but not all, patients with MS experience some degree of persistent disability that gradually worsens over time. In some patients, disability may progress independent of relapses, a process termed secondary progressive multiple sclerosis (SPMS). In the first few years of this process, many patients continue to experience relapses, a phase of the disease described as active SPMS. Active SPMS is one of the relapsing forms of MS, and drugs approved for the treatment of relapsing forms of MS can be used to treat active SPMS. Later, many patients with SPMS stop experiencing new relapses, but disability continues to progress, a phase called non-active SPMS. To read more on this subject and review details on the trail performed, click here http://www.medscape.com And for additional information, click here https://www.fda.gov/
Brighter Tomorrow Grant accepting applications June 1
MS Focus will be accepting applications for the Brighter Tomorrow Grant program June 1 through Sept 1. Each year, MS Focus makes dreams come true for people with MS through this program by providing goods and services – valued at up to $1000.00 per recipient – to people with MS nationwide. The goal is to improve the quality of life for people with MS by enhancing their safety, self-sufficiency, comfort, or well-being.
To qualify applications will be available by calling MS Focus at 888-673-6287 or at http://msfocus.org
Keeping your cool
Overheating may intensify MS symptoms, but cooling can offer significant relief. The MS Focus Cooling Program is now open and taking applications through June 1. Applications can be submitted online, by fax or through the mail. All applications are confidential and will be reviewed by the grant committee. For more information on the MS Focus Cooling Program, or to access these services, call 888-MSFOCUS (673-6287) or visit http://www.msfocus.org/Get Help
Ken Shafer not only had MS himself, but was a true champion and advocate for those with MS. He was an educator for 34+ years so we honor him with a yearly Bowl-a-thon to raise money for a yearly scholarship to be awarded to a local student affected by MS.
This years event will be held at the Vinton Bowling Center, 1200 Vinyard Rd in Vinton on Saturday, May 18th from noon to 4 pm. For just $10 you get three games and shoe rental. This is open to the public. There will be a special appearance by Craig Evans, food and door prizes.
Come and enjoy an afternoon of fun no matter your bowling skill!